WAT · Q2 2025 Earnings
BullishWaters Corporation
Reported August 4, 2025
30-second summary
Waters delivered 9% reported / 8% constant-currency revenue growth ($771M) with non-GAAP EPS of $2.95, raised full-year guidance on both sales and EPS, and used the call to frame the pending BD Biosciences & Diagnostic Solutions combination as a strategic accelerant. The replacement cycle in large pharma and CDMOs is real — Alliance IS sales grew 300% YoY and TQ Absolute XR is the fastest product launch in five years — but management is explicitly de-risking back-half instrument growth to 5% despite funnel strength. Operating margin at 24.4% (non-GAAP 29.1%) ran light due to geographic mix, tariff remediation, and a discrete tax item, all framed as transitory.
Headline numbers
EPS
Q2 FY2025
$2.95
Revenue
Q2 FY2025
$0.77B
+8.0% YoY
Gross margin
Q2 FY2025
58.3%
Free cash flow
Q2 FY2025
$0.02B
Operating margin
Q2 FY2025
24.4%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $0.77B | +8.0% |
| EPS | $2.95 | — |
| Gross margin | 58.3% | — |
| Operating margin | 24.4% | — |
| Free cash flow | $0.02B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Waters segment | $0.689B | +10.0% |
| TA segment | $0.082B | -6.0% |
| Instruments | $0.308B | +4.0% |
| Service | $0.298B | +9.0% |
| Chemistry | $0.165B | +16.0% |
| Pharmaceutical | $0.462B | +11.0% |
| Industrial | $0.238B | +6.0% |
| Academic & Government | $0.072B | -3.0% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Asia | $0.266B | +14.0% |
| Americas | $0.281B | +2.0% |
| Europe | $0.225B | +8.0% |
| Recurring revenue | $462.9 million | — |
| Recurring revenue growth (constant currency) | 11% | — |
| Operating margin | 24.4% | — |
| Adjusted non-GAAP operating margin | 29.1% | — |
Management tone
Management's posture in Q&A was confident on demand and deliberately conservative on the guide. The recurring pattern across the exchanges: analysts probed why back-half instrument growth is assumed at ~5% when funnels are described as "exceptional" and TQ Absolute XR is "the fastest product launch in five years." The answer in each case was that the assumption is a de-risking choice, not a demand signal. That stance — raising guidance while baking in conservatism — reads as a setup for upside revisions if momentum holds.
The BD Biosciences & Diagnostic Solutions deal moved from announcement to operating narrative this quarter. Management quantified the synergy bridge in unusual detail: $345M adjusted EBITDA synergies by year five ($200M cost by year three, $290M revenue by year five), a 180bps competitive growth gap in microbiology to be closed via the Waters commercial playbook, and a 700bps gross-margin gap to be addressed via BD's existing plan accelerated by Waters. In prepared remarks, management broke the $290M revenue synergy target into $150M from commercial excellence, $115M from high-growth adjacencies, and $60M from cross-selling — with the operations turnaround and gross-margin expansion described as NOT underwritten in the deal model and framed as upside. Chris Ross, SVP of Global Operations, was named to lead the integration office, with management drawing a direct line to the EMD Millipore–Sigma-Aldrich integration playbook. A $400-500M microbiology mass-spec TAM was floated with a 2-3 year earliest product timeline.
On margin, management was direct that Q2 operating margin pressure came from geographic mix, tariff remediation costs, and a 5-cent EPS discrete tax item — all positioned as normalizing in H2 with progressive Q3-Q4 improvement and volume leverage in Q4. The $8M pull-forward from customer safety-stock building was acknowledged with low conviction on timing ("may not materialize in 2025"), which is a more honest tell than the typical "transitory" framing.
Q&A highlights
Jack Meehan · Nefron
Unpacking high single-digit LC-MS growth in Waters segment instruments, replacement cycle status, competitive dynamics, and Alliance IS performance. Also asked about mass spec MALDI microbiology opportunity timeline, product launch expectations, and FDA strategy.
LC-MS grew high single digits across pharma and industrial, driven by strong replacement cycles in large pharma and CDMO growth. Alliance IS grew 300% YoY. TQ Absolute XR showed exceptional robustness (30,000 injections vs. prior 3,000). On microbiology, mass spec development will take 3-5 years, with earliest product introduction in 2-3 years. $400-500M TAM identified. Operations turnaround and gross margin expansion not included in deal model.
Tycho Peterson · Jefferies
Probed LCMS growth deceleration from mid-teens Q1 to high single digits Q2 amid difficult back-half comps. Asked about TQ XR impact from ASMS launch and TA Americas decline of 20%.
No slowdown in replacement cycle assumed; downstream QAQC position insulates from MFN trends. TQ XR exceeded expectations, fastest product launch in five years, displacing competitors in DMPK labs. TA Americas declined 20% due to macroeconomic conditions and tariff challenges impacting material science/polymer customers. Back-half instrument growth assumed conservatively at 5% despite strong momentum. Q3-Q4 ramp consistent with prior year.
Rachel Vattenstahl · JP Morgan
Operating margin lighter than Street expected despite solid recurring revenue. Asked about tariff impact on gross margin, margin trajectory Q3-Q4, and $8M pull-forward conviction and timing.
Margin pressure primarily on gross margin line from geographical mix and tariff remediation costs. Tax rate was 5-cent EPS headwind from discrete quarterly items expected to normalize in H2. Progressive margin improvement Q3-Q4 with volume leverage in Q4. Pull-forward conviction based on order pattern analysis and customer discussions; $8M likely split evenly Q3-Q4 but timing uncertain. Some pull-forward may not materialize in 2025.
Catherine Schultz · Baird
Asked how $115M commercial excellence revenue synergies split between biosciences vs. diagnostics and across instrument replacement, e-commerce, and service attach. Also probed confidence in repeating Waters turnaround success in BD microbiology given 180bps competitive underperformance.
Instrument replacement largely biosciences; e-commerce and service attach spread across both. Microbiology underperformance (180bps vs. competitor) attributed to 100bps pricing conservatism and 80bps operational drag. Next-gen BACTEC launch and pricing improvement expected to drive ~100bps recovery. Remaining 80bps comes from service attach and e-commerce. 700bps gross margin gap being addressed through BD's existing plan, to be accelerated by Waters. Turnaround not underwritten in synergy model.
Dan Brennan · TD Cowen
LCMS back-half growth assumptions given strong Q1 comps and book-to-bill above one. Asked about funnel strength and whether China's strong Q2 (beating guidance) might face headwinds, or was it permanent improvement.
Exceptional funnels across large pharma, CDMOs (especially US, China), and India generics. LC growing strong; mass spec (TQ Absolute/XR) penetrating new DMPK segment in plasma testing. Back-half instrument growth conservatively assumed at 5% despite strong momentum, with Q3-Q4 ramp in line with prior year (de-risking approach). China strength driven by CDMO pickup, battery testing, localized portfolio, modest stimulus. Maintaining conservative low-to-mid single-digit China growth guide for back-half to avoid over-extrapolation from two data points.
What to watch into next quarter
Whether back-half instrument growth materially exceeds the 5% baked-in assumption — funnel commentary suggests upside, and Q3 print will be the first test
TA segment trajectory, particularly TA Americas — down 20% this quarter on tariff/macro; watch whether sequential improvement appears or the weakness deepens
Gross margin recovery now that tariff remediation costs are flowing through; Q3 should show the first leg of management's "progressive Q3-Q4" margin improvement claim
China growth — watch whether the low-to-mid single-digit H2 guide proves conservative versus the +14% Asia print this quarter
BD Biosciences deal close timing and any incremental color on the microbiology mass-spec product roadmap (2-3 year earliest timeline cited)
Realization of the $8M pull-forward — management flagged uncertainty on whether it lands in 2025; watch for explicit Q3 commentary
Sources
- Waters Corporation Q2 2025 press release (Form 8-K Exhibit 99.1), filed via SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1000697/000119312525172076/d26754dex991.htm
- Q2 2025 earnings call prepared remarks and Q&A
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.